此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

2026年10月13日 更新者:Vertex Pharmaceuticals Incorporated

A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

研究概览

详细说明

The study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581 in healthy participants and in participants with CF. VX-581 will be administered alone and in combination with TEZ and D-IVA. The study consists of Screening Phase, Run-In Phase (CF only), Treatment Phase and Safety Follow-up Phase.

Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

研究类型

介入性

注册 (估计的)

152

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Kansas
      • Overland Park、Kansas、美国、66212
        • 招聘中
        • Altasciences - Kansas City

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Parts A, B, C:

    • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
    • A total body weight of more than (>) 50 kg
  • Part D:

    • Confirmed diagnosis of CF

Key Exclusion Criteria:

  • Parts A, B, C:

    • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
    • Any condition possibly affecting drug absorption
  • Part D:

    • History of clinically significant cirrhosis with or without portal hypertension.

Other protocol defined Inclusion/Exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Part A: Single Ascending Dose

Participants will be randomized to receive a single dose of VX-581.

Suspension for Oral Administration.

Tablets for Oral Administration.

安慰剂比较:Placebo: Part A

Participants will be randomized to receive a single dose of placebo matched to VX-581.

Suspension for Oral Administration.

实验性的:Part B: Multiple Ascending Dose

Participants will be randomized to receive multiple doses of VX-581.

Suspension for Oral Administration.

Tablets for Oral Administration.

安慰剂比较:Placebo: Part B

Participants will be randomized to receive multiple doses of placebo matched to VX-581.

Suspension for Oral Administration.

实验性的:Part C: VX-581 with TEZ/D-IVA or D-IVA

Participants will be randomized to receive multiple doses VX-581 in combination with TEZ/D-IVA or D-IVA.

Suspension for Oral Administration.

Tablets for Oral Administration.

Tablet for Oral Administration.

其他名称:
  • VX-561
  • deutivacaftor

Tablet for Oral Administration.

其他名称:
  • VX-661
  • 特扎卡夫托
安慰剂比较:Placebo: Part C

Participants will be randomized to receive placebo matched to VX-581 in combination with TEZ/D-IVA or D-IVA.

Suspension for Oral Administration.

Tablet for Oral Administration.

其他名称:
  • VX-561
  • deutivacaftor

Tablet for Oral Administration.

其他名称:
  • VX-661
  • 特扎卡夫托
实验性的:Part D: VX-581 with TEZ/D-IVA or D-IVA in CF

Participants with CF will enter a run-in period and receive ELX/TEZ/IVA. Following the run-in period participants will receive VX-581 in combination with TEZ/D-IVA or D-IVA in the treatment period. Following the treatment period, participants will enter a 14-day Washout Period and receive ELX/TEZ/IVA. (Part D will be open-label)

Suspension for Oral Administration.

Tablets for Oral Administration.

Tablet for Oral Administration.

其他名称:
  • VX-561
  • deutivacaftor

Tablet for Oral Administration.

其他名称:
  • VX-661
  • 特扎卡夫托

Fixed dose combination (FDC) Tablets for Oral Administration.

其他名称:
  • VX-445/VX-661/VX-770
  • elexacaftor/tezacaftor/ivacaftor

Tablet for Oral Administration.

其他名称:
  • VX-770
  • 伊凡卡托

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From Day -1 up to Day 8
From Day -1 up to Day 8
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From Day -1 up to Day 17
From Day -1 up to Day 17
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From Day -1 up to Day 17
From Day -1 up to Day 17
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:From Signing of Informed Consent up to Day 105
From Signing of Informed Consent up to Day 105

次要结果测量

结果测量
大体时间
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-581
大体时间:On Day 1
On Day 1
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) Post-Dose of VX-581
大体时间:On Day 1
On Day 1
Part B: Cmax of VX-581
大体时间:On Days 1, 7, and 10
On Days 1, 7, and 10
Part B: AUC0-24h Post-Dose of VX-581
大体时间:On Days 1, 7, and 10
On Days 1, 7, and 10
Part C: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
大体时间:On Days 1, 7, and 10
On Days 1, 7, and 10
Part C: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
大体时间:On Days 1, 7, and 10
On Days 1, 7, and 10
Part D: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
大体时间:On Day 1 and Day 28
On Day 1 and Day 28
Part D: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
大体时间:On Day 1 and Day 28
On Day 1 and Day 28
Part D: Absolute Change in Sweat Chloride (SwCl)
大体时间:From Baseline Up To Day 28
From Baseline Up To Day 28

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月9日

初级完成 (估计的)

2027年7月12日

研究完成 (估计的)

2027年7月12日

研究注册日期

首次提交

2025年12月4日

首先提交符合 QC 标准的

2025年12月4日

首次发布 (实际的)

2025年12月16日

研究记录更新

最后更新发布 (实际的)

2026年10月19日

上次提交的符合 QC 标准的更新

2026年10月13日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅